New research showed that the BNT162b2 XBB vaccine was capable of reducing hospitalizations and emergency department and urgent care visits due to COVID-19 in children aged 5 to 17 years.
COVID-19 infections were associated with greater risk of hospitalization, complications, and mortality in patients with peripartum and hypertrophic cardiomyopathy.